106 related articles for article (PubMed ID: 2552802)
21. [A clinical phase III trial of ulinastatin (MR-20) for nephrotoxicity of cisplatin].
Nishikawa H; Nakabayashi T; Nakai Y; Kurita Y; Fukuoka M; Onoshi T; Ogura T; Sakuma A; Niitani H; Tsubura E
Gan To Kagaku Ryoho; 1998 Jan; 25(1):97-109. PubMed ID: 9464335
[TBL] [Abstract][Full Text] [Related]
22. [Therapeutic effects and influence on the urinary enzyme activity of human urinary trypsin inhibitor (urinastatin) in cases with acute renal failure--changes in the urinary activities of NAG and AAP].
Soejima A; Suzuki M; Kamiya K; Motohasi S; Nakabayashi K; Kitamoto K; Nagasawa T
Nihon Jinzo Gakkai Shi; 1989 Sep; 31(9):985-90. PubMed ID: 2573748
[TBL] [Abstract][Full Text] [Related]
23. Urinary excretion of beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase in advanced neuroblastoma patients receiving cis-diamminedichloroplatinum(II).
Ikeda H; Nagashima K; Okumura H; Takahashi A; Matsuyama S; Nagamachi Y
Eur J Surg Oncol; 1988 Feb; 14(1):17-20. PubMed ID: 3278937
[TBL] [Abstract][Full Text] [Related]
24. [Protective effect of urinastatin on ischemic renal injury in rabbits].
Kihara K; Nagata N; Takasaki M
Nihon Jinzo Gakkai Shi; 1991 Jul; 33(7):673-7. PubMed ID: 1684217
[TBL] [Abstract][Full Text] [Related]
25. Urinary beta 2-microglobulin: early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide.
de Gislain C; Dumas M; d'Athis P; Lautissier JL; Escousse A; Guerrin J
Cancer Chemother Pharmacol; 1986; 18(3):276-9. PubMed ID: 3542269
[TBL] [Abstract][Full Text] [Related]
26. The ameliorative effect of cysteine prodrug L-2-oxothiazolidine-4-carboxylic acid on cisplatin-induced nephrotoxicity in rats.
Ali BH; Al Moundhri MS; Tag Eldin M; Nemmar A; Tanira MO
Fundam Clin Pharmacol; 2007 Oct; 21(5):547-53. PubMed ID: 17868208
[TBL] [Abstract][Full Text] [Related]
27. Early and quantitative detection of cisplatin-induced nephrotoxicity by measurement of plasma PSP (phenolsulfonphthalein) half-life in rats.
Uozumi J; Ueda T; Koikawa Y; Yasumasu T; Kumazawa J
Nihon Jinzo Gakkai Shi; 1993 Aug; 35(8):901-4. PubMed ID: 8254999
[TBL] [Abstract][Full Text] [Related]
28. [Prophylactic effect of ulinastatin on cisplatin-induced renal disorders in lung cancer patients].
Horiguchi T; Kasahara J; Ogura K; Handa M; Hosoda H; Shakato A; Tachikawa S; Sato M; Suetsugu S; Umeda H
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Jan; 30(1):12-9. PubMed ID: 1625386
[TBL] [Abstract][Full Text] [Related]
29. Protective effect of fleroxacin against the nephrotoxicity of isepamicin in rats.
Yazaki T; Yoshiyama Y; Wong P; Beauchamp D; Kanke M
Biol Pharm Bull; 2002 Apr; 25(4):516-9. PubMed ID: 11995935
[TBL] [Abstract][Full Text] [Related]
30. The protective effect of methylprednisolone against cisplatin-induced nephrotoxicity in patients with urothelial tumors.
Uozumi J; Koikawa Y; Yasumasu T; Tokuda N; Kumazawa J
Int J Urol; 1996 Sep; 3(5):343-7. PubMed ID: 8886909
[TBL] [Abstract][Full Text] [Related]
31. [Measurement of creatinine clearance and urinary NAG for the evaluation of cis-platinum induced nephrotoxicity].
Kubota A; Yoshida T; Tsukuda M; Furukawa S; Miyata K; Mochimatsu I; Sawaki S
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2599-605. PubMed ID: 2774590
[TBL] [Abstract][Full Text] [Related]
32. Follow-up study of enzymuria and beta 2 microglobulinuria during cis-platinum treatment.
Tirelli AS; Colombo N; Cavanna G; Mangioni C; Assael BM
Eur J Clin Pharmacol; 1985; 29(3):313-8. PubMed ID: 3908127
[TBL] [Abstract][Full Text] [Related]
33. Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats.
Nakamura T; Kokuryo T; Hashimoto Y; Inui KI
J Pharm Pharmacol; 1999 Feb; 51(2):227-32. PubMed ID: 10217324
[TBL] [Abstract][Full Text] [Related]
34. [A clinical evaluation of the protective effect of fosfomycin (FOM) against the cis-diamminedichloroplatinum (CDDP)-induced nephrotoxicity].
Saito M; Masaki T; Kato H; Numasaka K
Hinyokika Kiyo; 1988 May; 34(5):782-9. PubMed ID: 3051938
[TBL] [Abstract][Full Text] [Related]
35. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
36. Protection against cisplatin-induced nephrotoxicity by Spirulina in rats.
Mohan IK; Khan M; Shobha JC; Naidu MU; Prayag A; Kuppusamy P; Kutala VK
Cancer Chemother Pharmacol; 2006 Dec; 58(6):802-8. PubMed ID: 16552571
[TBL] [Abstract][Full Text] [Related]
37. [A clinical phase III trial of MR-20 in gynecologic nephrotoxicity of cisplatin--a comparative study in MR-20-treated and control patients on cyclical intermittent cisplatin treatment].
Ochiai K; Ikeda M; Kobayashi H; Nishimura H; Shibasaki T; Sakai O; Oh-hashi Y; Terashima Y
Gan To Kagaku Ryoho; 1998 Apr; 25(5):713-22. PubMed ID: 9571969
[TBL] [Abstract][Full Text] [Related]
38. The evaluation of cisplatin effect on tubular function in children on chemotherapy.
Zareifar S; Jafari H; Geramizadeh B; Basiratnia M; Golafshan H; Cohan N; Mehravar Z; Hamidi R
Pediatr Hematol Oncol; 2013 Feb; 30(1):18-24. PubMed ID: 23163346
[TBL] [Abstract][Full Text] [Related]
39. Xanthorrhizol has a potential to attenuate the high dose cisplatin-induced nephrotoxicity in mice.
Kim SH; Hong KO; Hwang JK; Park KK
Food Chem Toxicol; 2005 Jan; 43(1):117-22. PubMed ID: 15582203
[TBL] [Abstract][Full Text] [Related]
40. [Effects of urinastatin on prevention of cisplatin induced nephrotoxicity].
Sasa H; Hisano A; Kudo K; Kuki E; Miyauchi M; Kita T; Kikuchi Y; Tode T; Furuya K; Nagata I
Gan To Kagaku Ryoho; 1991 Dec; 18(15):2623-5. PubMed ID: 1746976
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
